Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Getein BiotechSHSE:603387 +2.18%77 Operating Margin % is 31.28% as of Mar. 2026, which is 1% above its 10-year median of 31.03. GuruFocus rates SHSE:603387 with a GF Score™ of 77/100 and a GF Value™ of ¥7.57 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Getein Biotech ranks better than 91.67% on this metric.
Getein Biotech Inc operating margin has been in a 5-year decline. The average rate of decline per year is -6.7%.
The historical rank and industry rank for Getein Biotech's Operating Margin % or its related term are showing as below:
SHSE:603387'
s Operating Margin % Range Over the Past 10 Years
Min: 19.59 Med: 31.03 Max: 44.1
Current: 24.84
SHSE:603387's Operating Margin % is ranked better than 91.67% of 816
companies
in the Medical Devices & Instruments industry
Industry Median: 3.28
vs SHSE:603387: 24.84
Getein Biotech's 5-Year Average Operating Margin % Growth Rate was -6.70% per year.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Getein Biotech Operating Margin % Related Terms
Getein Biotech Operating Margin % Historical Data
* Premium members only.
The historical data trend for Getein Biotech's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:603387 vs ABT, SYK, MDT: Operating Margin % Comparison
For the Medical Devices subindustry, Getein Biotech's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Getein Biotech Operating Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Getein Biotech's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Getein Biotech's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Getein Biotech's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Getein Biotech (SHSE:603387) has a Operating Margin % of 31.28% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Getein Biotech and its competitors. This is near median its historical median of 31.03. Over the past decade, Getein Biotech's Operating Margin % has ranged from 19.59 to 44.10. According to the industry distribution chart, Getein Biotech ranks #68 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 8.3%.
Is Getein Biotech's Operating Margin % too high?
Getein Biotech's current Operating Margin % of 31.28% is near median its 10-year median of 31.03. Over the past 10 years, this metric has ranged from a low of 19.59 to a high of 44.10. The Medical Devices & Instruments industry median Operating Margin % is 3.28. Getein Biotech's value of 31.28% is 853.7% above this industry median. Based on the distribution chart, Getein Biotech ranks #68 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Getein Biotech has a GF Score™ of 77/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Getein Biotech's Operating Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Getein Biotech ranks #68 out of 816 companies for Operating Margin %. This places Getein Biotech in the top 8% of its industry — outperforming the majority of peers. The industry median Operating Margin % is 3.28. Getein Biotech's value of 31.28% is 853.7% above this benchmark. Historically, Getein Biotech's own Operating Margin % has ranged from 19.59 to 44.10 over the past decade. While the company's 10-year median is 31.03 vs. the industry median of 3.28, Getein Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Medical Devices & Instruments company?
The median Operating Margin % among Medical Devices & Instruments companies is 3.28, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Getein Biotech's current Operating Margin % of 31.28% is 853.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Getein Biotech and its competitors. For the Medical Devices & Instruments industry, the median Operating Margin % is 3.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Getein Biotech's current Operating Margin % is 31.28%, which is near median its own 10-year median of 31.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Getein Biotech stock overvalued right now?
Based on GuruFocus' analysis, Getein Biotech (SHSE:603387) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥7.57, compared to a current price of ¥8.90 — trading 17.6% above its estimated fair value. The current Operating Margin % is 31.28%, which is near median its 10-year median of 31.03 and 853.7% above the Medical Devices & Instruments industry median of 3.28. Getein Biotech's overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Getein Biotech (SHSE:603387), the current Operating Margin % is 31.28% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Getein Biotech (SHSE:603387) Overvalued in 2026?
Based on GuruFocus' analysis, Getein Biotech stock appears to be overvalued.
The current stock price of ¥8.90 is trading 17.6% above its estimated GF Value™ of ¥7.57.
GuruFocus considers Getein Biotech to be Modestly Overvalued.
Key valuation signals for SHSE:603387:
Operating Margin %: 31.28% (near median its 10-year median of 31.03)
GF Value™: ¥7.57 vs. price of ¥8.90 (17.6% above fair value)
Industry Position: 853.7% above the Medical Devices & Instruments median (#68 of 816)
No single metric tells the full story. See the SHSE:603387 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Getein Biotech Inc is an in-vitro diagnostic company. It is specializing in analytical medical devices and point-of-care testing kits. Its product lines consist of cardiovascular, inflammatory, diabetes, fertility, renal, liver and specialty assays.
77GF Score
Get the complete analysis for SHSE:603387
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603387 has been successfully added to your 
